Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

harmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this rele
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... RealMed has been ranked the ... 2009 Top 20 Best in KLAS ... RealMed is a dynamic revenue cycle management ... between healthcare providers and all ... specializing in vendor performance measurement in the ...
(Date:12/16/2009)... CareCentrix, Inc ., the nation,s leading provider ... that it has been awarded Health Utilization Accreditation ... organization that establishes quality standards for the health ... trained, qualified clinical personnel conduct and oversee the ... appeals process is in place, and that medical ...
(Date:12/16/2009)... 16 Siemens Healthcare today ... to help healthcare ... deadlines defined within the HITECH provision of ... Featuring zero-percent interest terms for ... defer up-front payments associated with their technology ...
Breaking Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3CareCentrix Receives URAC Health Utilization Management Accreditation 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4Insulet Corporation to Present at Upcoming Investor Conferences 53953 1Insulet Corporation to Present at Upcoming Investor Conferences 53953 2Garry OGrady Appointed Senior Vice President and General Manager of Pharmaceutical Institute 53951 1Garry OGrady Appointed Senior Vice President and General Manager of Pharmaceutical Institute 53951 2Delays in UK child brain tumor diagnosis 53949 1Delays in UK child brain tumor diagnosis 53949 2
... 15 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ) ... timing,of its announcement of results for the CLIRS ... (omiganan pentahydrochloride 1% topical gel),for the prevention of ... discussions with the U.S. Food and Drug,Administration (FDA) ...
... DURHAM, N.C., Sept. 15 Less than ... are eventually published in,medical journals, according to a ... (LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ), Drs. ... Washington and,Fred Hutchinson Cancer Research Center, Seattle, searched ...
Other Medicine Technology:Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline 2Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline 3Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline 4Most Cancer Treatment Studies Aren't Published, Study Finds 2Most Cancer Treatment Studies Aren't Published, Study Finds 3
(Date:12/17/2009)... science-based products from MediNiche provide alternative natural relief prior to ... ... MO (PRWEB) December 17, 2009 -- D-Psoria products ... and flaking associated with severe skin conditions . ... the U.S. by MediNiche Pharmaceuticals, St. Louis, Missouri., ...
(Date:12/17/2009)... & Nathan law firm, litigators of complex personal injury and insurance ... , ... Tulsa, OK (Lexis Nexis) December 17, 2009 -- ... 20 years of experience handling personal injury and insurance coverage disputes, ... the top attorneys in the state of Oklahoma for 2009-2010., , ...
(Date:12/16/2009)... -- Health care sector revenue increased by 5.7 ... $1.66 trillion in 2007, according to new data ... classified under the North American Industry Classification System ... ,, These figures come from the 2008 ... , a series of tables which provides estimates ...
(Date:12/16/2009)... CHASE, Md., Dec. 16 New Enterprise ... firm, today announced that one of its portfolio ... agreement to be acquired by Ethicon, Inc., a ... for approximately $785 million (net of estimated cash ... technology company dedicated to designing, developing and commercializing ...
(Date:12/16/2009)... has never felt so good for "The Biggest Loser" ... means continuing to make smart choices everyday to help ... healthy choice that is an important part of living ... Every glass of milk has nine essential nutrients like ... blood pressure, and calcium and vitamin D for strong ...
Breaking Medicine News(10 mins):Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3
... uncovered the secrets of the deadly Spanish flu that in 1918 ... ,The pandemic took lives of more people than ... virus was not understood then. ,Dr John Kash, of the University ... infecting mice with a reconstructed form of the 1918 virus and ...
... the September 27 issue of JAMA says that initial ... HIV positive patients has little or no effect on ... conflicts in opinion as to when antiretroviral therapy must ... of progressive human immunodeficiency virus (HIV) disease and a ...
... the turn of the 20th century, tobacco baron James Duke ... of 430 million, jabbed his finger at a map of ... sell cigarettes." ,One hundred years on, Duke's prophesy about ... has since grown to 1.3 billion, has been realised on ...
... from the Johns Hopkins University and other institutions have ... as Lynch syndrome// , which predisposes families to develop ... an individual’s detailed family history of colorectal and endometrial ... manifest themselves—in the form of tumors. It can assess ...
... of food labels and test if it meets the ... Services //embarked on a survey involving 200 primary care ... reading food-labels, as a prelude to making a purchase, ... that consumers often check on food labels would most ...
... of employers has revealed that premiums for employer-based health ... inflation and wages, Fo the seventh straight year.// ... group and the Health Research and Educational Trust released ... premium increase was 7.7 percent, in 2006, the least ...
Other Medicine News:Health News:Spanish flu virus – secrets uncovere 2Health News:HIV RNA Level Seen As Little Value In Predicting Treatment 2Health News:World's 3 out of 10 Cigarettes Smoked in China 2Health News:Model Predicts Colon Cancer Inheritable Genetic Defects 2Health News:Premiums for Health insurance Soar 2
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... Used for catheter positioning and exchange in ... the wire guide coils allows utilization of ... smooth transition to a very flexible tip. ... is the most rigid coiled wire guide ...
... Used for catheter positioning ... procedures. Increased inner diameter ... allows utilization of an ... while maintaining tip flexibility. ...
Medicine Products: